Last reviewed · How we verify

lithium plus carbamazepine

University of Sao Paulo · FDA-approved active Small molecule

Lithium and carbamazepine together modulate mood through distinct mechanisms: lithium alters intracellular signaling and neurotransmitter activity, while carbamazepine acts as a sodium channel blocker and anticonvulsant.

Lithium and carbamazepine together modulate mood through distinct mechanisms: lithium alters intracellular signaling and neurotransmitter activity, while carbamazepine acts as a sodium channel blocker and anticonvulsant. Used for Bipolar disorder (acute and maintenance treatment), Treatment-resistant bipolar depression.

At a glance

Generic namelithium plus carbamazepine
SponsorUniversity of Sao Paulo
Drug classMood stabilizer combination
TargetLithium: inositol monophosphatase and GSK-3β; Carbamazepine: voltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPsychiatry
PhaseFDA-approved

Mechanism of action

Lithium affects second-messenger systems and reduces inositol levels, influencing serotonin and norepinephrine neurotransmission. Carbamazepine blocks voltage-gated sodium channels and has anticonvulsant properties that stabilize neuronal membranes. The combination is used in bipolar disorder to enhance mood stabilization through complementary mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results